MedTrace Logo

Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

NCT04351932 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2020-04-17

No results posted yet for this study

Summary

Mesenchymal stem cells (MSC) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as umbilical cord, bone marrow, and adipose tissue. The multipotent properties of MSCs make them a promising option for the treatment of osteoarthritis (OA).

Bone marrow mesenchymal stem cells (BM-MSC) and adipose derived mesenchymal stem cells (AD-MSC) have been used separately to treat OA. The aim of the present study will be to compare in a randomized non blind controlled clinical trial 3 types of intra-articular injections containing MSC populations obtained from two clinically relevant sources: BM-MSC, AD-MSC and a combination of both BM-MSC and AD-MSC.

Conditions

  • Osteo Arthritis Knee

Interventions

BIOLOGICAL

bone marrow mesenchymal stem cells

intrarticular bone marrow mesenchymal stem cells injection

BIOLOGICAL

Adipose Mesenchymal stem cells

intrarticular adipose mesenchymal stem cells injection

BIOLOGICAL

bone marrow & adipose mesenchymal stem cells injection

intrarticular bone marrow and adipose stem cells injection.

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER

  • Universidad Catolica Santiago de Guayaquil

    lead OTHER

Principal Investigators

  • Carlos A Chiriboga, MD · Universidad Católica Santiago de Guayaquil

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-07
Primary Completion
2021-06-07
Completion
2021-09-07

Countries

  • Ecuador

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351932 on ClinicalTrials.gov